This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

  •  
  •  
  •  
  •  
  •  
  •  

Phase III

Phase II

  • Edivoxetine (e" di vox' e teen hye" droe klor' ide)
    LY2216684 (edivoxetine) is a chemical entity that inhibits the reuptake of norepinephrine. LY2216684 is being studied for multiple CNS disorders. Molecule is owned by a 3rd party, Lilly retains rights.

    For more information on edivoxetine clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Florbenazine (flor ben' a zeen)
    Florbenazine (18F-AV-133) is a chemical entity PET imaging agent being studied for the imaging of Parkinson's disease pathology.

    For more information on 18F-AV-133 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase I

  • A ß antibody Fab PEG Alzheimer's
    "A b Antibody Fab PEG" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • BACE inhibitor Alzheimer's
    "BACE Inhibitor" is a new chemical entity being studied for the treatment of Alzheimer's disease.

     
  • D1 potentiator
    "D1 potentiator" is a new chemical entity being studied for the treatment of dementia.

     
  • N3pG-Aß Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Tau Antibody
    "Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Pomaglumetad methionil
    LY2140023 monohydrate (pomaglumetad methionil) is a chemical entity agonist of the metabotropic glutamate 2/3 receptors. LY2140023 licensed to Denovo Biopharma to identify genetic biomarkers and to screen for appropriate patient subsets for further study in future clinical trials.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 19, 2016. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • NME
  • Select NILEX
  • Diagnostic